SCHEMBL2315754

SCHEMBL2315754

CCc1noc2cc3c(cc12)CCNCC3

nearest known ligand 0.38

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ HRH1 P35367 1/20 0.38
▸ DRD3 P35462 1/20 0.38
▸ KCNH2 Q12809 1/20 0.38
▸ ADCY6 O43306 1/20 0.35
▸ ADCY3 O60266 1/20 0.35
▸ ADCY9 O60503 1/20 0.35
▸ ADCY5 O95622 1/20 0.35
▸ ADCY8 P40145 1/20 0.35
▸ ADCY7 P51828 1/20 0.35
▸ ADCY2 Q08462 1/20 0.35
▸ ADCY1 Q08828 1/20 0.35
▸ ADCY4 Q8NFM4 1/20 0.35
▸ GRM4 Q14833 1/20 0.34
▸ CHRNB2 P17787 1/20 0.33
▸ CHRNA4 P43681 1/20 0.33
▸ HTR2C P28335 6/20 0.32
▸ HTR2B P41595 6/20 0.32
▸ HTR2A P28223 4/20 0.32
▸ MAPT P10636 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2307434 0.79 CHRNB2 (0.53) HRH1DRD3KCNH2ADCY6ADCY3
SCHEMBL7838860 0.76 HRH3 (0.42) —
SCHEMBL719750 0.69 DRD2 (0.45) ADCY6ADCY3ADCY9ADCY5ADCY8
SCHEMBL9688681 0.69 ALDH1A1 (0.32) —
SCHEMBL2312623 0.68 HTR2C (0.41) HRH1DRD3KCNH2ADCY6ADCY3
SCHEMBL2309199 0.66 DRD3 (0.41) DRD3KCNH2ADCY6ADCY3ADCY9
SCHEMBL17233224 0.65 MAPT (0.47) GRM4HTR2CMAPT
SCHEMBL721243 0.65 DRD2 (0.41) ADCY6ADCY3ADCY9ADCY5ADCY8
SCHEMBL8262760 0.64 ESR1 (0.40) GRM4MAPT
SCHEMBL24410388 0.64 DRD2 (0.47) GRM4HTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1751163-B1 BENZAZEPINE COMPOUNDS HAVING AFFINITY FOR DOPAMINE D3 RECEPTOR AND USES THEREOF GLAXO GROUP LTD (GB) 2011-08-10 — — EP disclosed
EP-1751163-B1 BENZAZEPINE COMPOUNDS HAVING AFFINITY FOR DOPAMINE D3 RECEPTOR AND USES THEREOF GLAXO GROUP LTD (GB) 2011-08-10 — — EP disclosed
US-7989444-B2 Compounds having affinity for dopamine D3 receptor and uses thereof GLAXO GROUP LIMITED (GB) 2011-08-02 — — US disclosed
US-7989444-B2 Compounds having affinity for dopamine D3 receptor and uses thereof GLAXO GROUP LIMITED (GB) 2011-08-02 — — US disclosed
US-7989444-B2 Compounds having affinity for dopamine D3 receptor and uses thereof GLAXO GROUP LIMITED (GB) 2011-08-02 — — US disclosed
US-20100016287-A1 COMPOUNDS HAVING AFFINITY FOR DOPAMINE D3 RECEPTOR AND USES THEREOF\ GLAXO GROUP LIMITED (GB) 2010-01-21 — — US disclosed
US-20100016287-A1 COMPOUNDS HAVING AFFINITY FOR DOPAMINE D3 RECEPTOR AND USES THEREOF\ GLAXO GROUP LIMITED (GB) 2010-01-21 — — US disclosed
US-20100016287-A1 COMPOUNDS HAVING AFFINITY FOR DOPAMINE D3 RECEPTOR AND USES THEREOF\ GLAXO GROUP LIMITED (GB) 2010-01-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100016287-A1 COMPOUNDS HAVING AFFINITY FOR DOPAMINE D3 RECEPTOR AND USES THEREOF\ DRD3, DRD2, SLC6A3 HRH1 879/4885DRD3 1/4885KCNH2 856/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback